Mitsubishi Tanabe pulls Radicava app after skeptical EU regulators ask for new trial
admin 31st May 2019 Uncategorised 0When Mitsubishi Tanabe’s Radicava got its nod from the FDA in 2016, it marked a turning point for ALS patients after 20 years without a new treatment on the market. But despite the hype—and with the drug’s eye-popping price tag in mind—Europe’s governing body wants to see more before it considers approval.
More: Mitsubishi Tanabe pulls Radicava app after skeptical EU regulators ask for new trial
Source: fierce